Pentoxifylline (Trental)

Subscribe to Selected New Research on Pentoxifylline

1568 relevant articles (218 outcomes, 359 trials/studies) found for this Drug

Description: A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production.

Also Known As:

Trental; Oxpentifylline; Agapurin; BL-191; Torental; BL 191; BL191; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

1-(5-hydroxy-5-methylhexyl)-3-methylxanthine: 13

torbafylline: 12

BB 1101: 11

1-(3'-carboxypropyl)-3,7-dimethylxanthine

1-(4'-carboxybutyl)-3,7-dimethylxanthine

8-oxolisofylline

8-oxopentoxifylline

lisofylline 4,5-diol

pentoxifylline-alpha-methoxy-alpha-(trifluoromethyl)phenylacetate ester

Experts

1.	Cesarone, M R: 11 articles (01/2002 - 01/2002)
2.	Incandela, L: 11 articles (01/2002 - 01/2002)
3.	Nicolaides, A N: 11 articles (01/2002 - 01/2002)
4.	Belcaro, G: 11 articles (01/2002 - 01/2002)
5.	Geroulakos, G: 11 articles (01/2002 - 01/2002)
6.	De Sanctis, M T: 11 articles (01/2002 - 01/2002)
7.	Coimbra, Raul: 10 articles (07/2008 - 11/2003)
8.	Tsai, Tun-Jun: 8 articles (09/2008 - 12/2002)
9.	Griffin, M: 8 articles (01/2002 - 01/2002)
10.	Ramaswami, G: 8 articles (01/2002 - 01/2002)

Related Diseases

1.	Intermittent Claudication 07/01/1988 - "Pentoxifylline, recently approved for the treatment of intermittent claudication, is hepatically cleared with a high degree of first-pass metabolism" 01/01/1983 - "The positive results derived from pentoxifylline treatment are significant because, for the first time, treadmill testing can prove the effectiveness of a hemorheologic drug, such as pentoxifylline, in the treatment of patients with intermittent claudication" 11/01/1984 - "Although pentoxifylline has been shown to be effective in the treatment of intermittent claudication, additional research is needed to determine its use as adjunctive therapy in patients with concurrent coronary or cerebrovascular disease." 09/01/1989 - "In summary, pentoxifylline improved function and symptoms in 13 of 22 geriatric patients with intermittent claudication; the drug was safe and well tolerated at the usual dosage in this geriatric patient population." 09/01/1987 - "In this controlled trial the subset of patients with severe intermittent claudication benefited from pentoxifylline therapy." Order ALL the reference details at left...
2.	Fibrosis (Cirrhosis) 11/01/2000 - "A statistically significant reduction of fibrosis was obtained with pentoxifylline when administered intraperitoneally rather than intravenously" 06/01/2006 - "The purpose of this study was to determine whether pentoxifylline (PTX) treatment for 4 weeks (16 mg/kg/day) could significantly attenuate the process of fibrosis in diaphragm muscle from mdx mice" 06/01/2004 - "PATIENTS AND METHODS: In an open label drug trial, we studied the effects of pentoxifylline (400 mg orally tid for 8 weeks) on 30 patients who displayed late, radiation-induced fibrosis at 1 to 29 years posttreatment (40 to 84 Gy)" 07/01/2003 - "Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis." 05/01/2007 - "Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis." Order ALL the reference details at left...
3.	Neoplasms (Cancer) 11/01/2003 - "Surprisingly, our study revealed that pentoxifylline significantly promoted C-26-derived metastatic tumor growth in liver" 11/01/2003 - "Moreover, some beneficial properties of pentoxifylline, which could be useful in cancer treatment, have been reported and a few clinical trials with oncological patients have been performed" 11/01/2003 - "Therefore, the aim of the present study was to evaluate the influence of pentoxifylline on tumor development" 10/01/2001 - "PURPOSE: In this study we investigated the effect of pentoxifylline (PTX) on tumor-induced neovascularization as well as on different steps involved in the angiogenic process" 09/01/1993 - "An experimental study of the possibilities of using pentoxifylline for the prevention of cancer at different sites]" Order ALL the reference details at left...
4.	Pain (Aches) 02/02/2007 - "Pentoxifylline, a non-specific cytokine inhibitor, has shown to be beneficial in inflammatory pain in both experimental and clinical studies" 03/01/1996 - "From further subgroup analysis excluding patients who had only slight pain at the entrance of the study, there was a significant improvement in rest pain in favour of Pentoxifylline following seven days of treatment" 01/01/1995 - "Results showed a significant reduction in rest pain with pentoxifylline, and outcome was not influenced by various prognostic factors" 01/01/1991 - "Of those patients taking pentoxifylline for eight weeks or more (n = 110), 64% noted some improvement, with 31% reporting increased claudication distance and 52% reduced claudication pain" 05/01/1985 - "Trental treatment resulted in patients with advanced POAD stages in improvement of red cell filterability, red cell aggregation, decrease of plasma viscosity, increase in absolute walking distance and relief from rest pain, suggesting that such patients are accessible to conservative treatment with hemorheologically active agents." Order ALL the reference details at left...
5.	Reperfusion Injury 04/01/1995 - "The severity of the tissue injury increased considerably after reperfusion of the ischemic intestine and pentoxifylline was effective in attenuating the reperfusion injury significantly." 12/01/2003 - "Pentoxifylline is as effective as leukocyte depletion for modulating pulmonary reperfusion injury." 04/01/2007 - "The aim of this study was to investigate the in vivo effect of pentoxifylline on leukocyte-endothelium interaction in ischemia reperfusion injury" 02/01/2002 - "CONCLUSIONS: The results of this study suggest that pentoxifylline treatment attenuates reperfusion damage on both side, possibly with its effects on blood flow and neutrophils" 06/01/1997 - "The aim of this study was to determine the effects of pentoxifylline (Ptx) in reperfusion injury of the small bowel as a leukocyte stabilizer, free radical scavenger, and microcirculatory regulator" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Pentoxifylline (Trental)
3.	Aspirin (Acetylsalicylic Acid)
4.	Adrenal Cortex Hormones (Corticosteroids)
5.	Vitamin E
6.	methylxanthine
7.	Thalidomide (Thalomid)
8.	buflomedil (Lofton)
9.	Nifedipine (Adalat)
10.	Cytokines

Related Therapies and Procedures

1.	Resuscitation
2.	Induced Heart Arrest (Cardioplegia)
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)
5.	Lymphatic Irradiation

Best Treatments:
Research Summary Report
on Intermittent Claudication

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 118 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>